

3<sup>rd</sup> Quarter of Fiscal 2015 Earnings Call

May 11, 2015





### Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties. Please refer to our press releases and our SEC filings for more information regarding the use of forward looking statements.



### Overview

# Long-term strategic partnerships gathering pace

- New relationships advancing
- Many existing partnerships broadening beyond original scope

# Becoming more selective towards large strategic partnerships

- Efficient signing of additional agreements with same partner
- Minimal sales and marketing
- Recurring revenue across multiple supply agreements
- Attractive operating margins





## Production Scale-Up and R&D Investment

Aligned with customer programs and new commercial opportunities

#### **Production Scale-Up**

- Multiple manufacturing lines
- Fit out of new cleanrooms
- Partnership with Flextronics

#### **R&D Investment Case Study**

- Integration of digital connectivity into select Unilife device platforms
  - Custom options include Bluetooth LE, 4G and WIFI
- Adding healthcare value and outcomes
  - Enhanced patient care
  - Improved rates of therapy adherence
  - Reduced healthcare costs



#### **Integrated Data Hubs**

HIPAA authorized stakeholders such as:

- **Patients**
- Payers
- Prescribers Pharmaceutical



### **Financial Results**

	Three Months Ended	
	<u>2015</u>	<u>2014</u>
Revenues	\$2.9MM	\$1.4MM
Research & development	\$13.2MM	\$8.0MM
Selling, general & administrative	\$9.1MM	\$6.6MM
Net loss per share	\$0.20	\$0.15
Adjusted net loss*	\$16.3MM	\$11.7MM
Adjusted net loss per share - diluted	\$0.14	\$0.12



## Summary

#### **Building Deep Customer Relationships**

- Growing base of new and existing customers
- Many evolving into strategic relationships

#### Investment in Production Scale-Up and R&D

- Expanding strength of team, operational capabilities and partnerships
- Prudent investment in R&D to extend competitive lead and penetrate other markets

#### **Building Value**

- Cash and revenue via new and existing customers supports path to sustainability
- Expected to generate significant commercial revenue with attractive operating margins over time



The Ocu-Mix™ syringe





# Questions





Final Comments

